30 Participants Needed

Neuromodulation for Depression

(TREND Trial)

AP
NB
AB
SC
Overseen ByStudy Coordinator
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The investigators will administer theta burst stimulation (TBS) in efforts to observe a decrease in severity of reported depression symptoms. A subset of participants will receive positive affect training during this intervention.

Will I have to stop taking my current medications?

Yes, you will need to stop taking certain medications. The trial excludes participants who are currently using Clozapine, Bupropion, prescription stimulants, benzodiazepines, or mood stabilizers.

What data supports the effectiveness of the treatment Theta Burst Stimulation (TBS) for depression?

Research shows that Theta Burst Stimulation (TBS), a type of transcranial magnetic stimulation, can be effective for treating depression, especially in patients who have not responded to other treatments. In one study, about 28% of patients achieved remission, and 52% showed significant improvement, indicating that TBS can be a promising option for treatment-resistant depression.12345

Is theta burst stimulation (TBS) safe for humans?

Research shows that theta burst stimulation (TBS), a type of brain stimulation, is generally safe and well-tolerated in people with depression. Some participants experienced mild headaches, but no serious side effects were reported.14678

How is Theta Burst Stimulation (TBS) different from other treatments for depression?

Theta Burst Stimulation (TBS) is a unique form of transcranial magnetic stimulation (TMS) that uses short bursts of magnetic pulses to stimulate the brain, potentially offering faster and more targeted treatment for depression compared to traditional TMS. It can be administered in accelerated schedules and has different protocols like intermittent (iTBS) and continuous (cTBS), which may enhance its effectiveness and convenience.13489

Research Team

EE

Erika E Forbes, Ph.D

Principal Investigator

University of Pittsburgh

Eligibility Criteria

This trial is for individuals with a current diagnosis of depression according to the DSM-5. Participants should not have used certain drugs like cocaine or MDMA recently, have high-risk suicidality, severe substance use disorders, specific medication usage (Clozapine, Bupropion), daily nicotine use, or a history of seizures and other listed conditions.

Inclusion Criteria

You are currently diagnosed with Depressive Disorder according to DSM-5.

Exclusion Criteria

You have consumed a large amount of alcohol within the past week or within the last 12 hours.
You have a mental health condition called obsessive-compulsive disorder, which you have had at any point in your life.
You have a history of mental illness that included losing touch with reality.
See 16 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants complete a baseline assessment before starting treatment

1 day

Treatment

Participants receive 20 theta burst stimulation (TBS) sessions over 2 weeks, with sessions delivered twice/day, 5 days/week

2 weeks
10 visits (in-person)

Post-TBS Assessment

Participants complete an assessment after the TBS treatment sessions

1 day

Follow-up

Participants are monitored for safety and effectiveness after treatment, with a follow-up assessment 4 months later

4 months

Treatment Details

Interventions

  • Theta Burst Stimulation
Trial OverviewThe TREND study is testing theta burst stimulation (TBS) as a treatment for depression. Some participants will also receive positive affect training alongside TBS to see if it helps reduce the severity of depression symptoms more effectively.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: TBSExperimental Treatment1 Intervention
In this open-label trial, all participants will undergo 2 continuous TBS (cTBS) sessions per visit over 10 days (weekdays, over 2 weeks; total = 20 TBS sessions in 10 visits). The total time of each pair of sessions (including pause between sessions) will be approximately 1 hour, with each session lasting approximately 100 seconds. There is only 1 group and 1 arm of the study. All participants will receive the treatment.

Theta Burst Stimulation is already approved in United States for the following indications:

🇺🇸
Approved in United States as Theta Burst Stimulation for:
  • Major Depressive Disorder

Find a Clinic Near You

Who Is Running the Clinical Trial?

Erika Forbes

Lead Sponsor

Trials
3
Recruited
180+

Findings from Research

In a randomized-controlled trial involving 32 patients with major depression, bilateral theta burst stimulation (TBS) to the dorsolateral prefrontal cortex showed a significant increase in treatment response compared to sham stimulation, with 9 responders in the TBS group versus 4 in the sham group.
The study also indicated a trend towards higher remission rates in the TBS group as measured by the Beck Depression Inventory, suggesting that TBS may enhance the effectiveness of ongoing medication and psychotherapy in treating major depression.
Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial.Plewnia, C., Pasqualetti, P., Große, S., et al.[2018]
In a randomized, double-blind trial involving 56 patients, intermittent theta burst stimulation (iTBS) over the dorsomedial prefrontal cortex showed a significant reduction in negative symptoms for patients with depression, but not for those with schizophrenia.
The treatment was generally safe and well-tolerated, with serious adverse events occurring only in the sham group, indicating that iTBS may be a promising intervention for depressive symptoms in certain patients.
Dorsomedial prefrontal theta burst stimulation to treat anhedonia, avolition, and blunted affect in schizophrenia or depression - a randomized controlled trial.Bodén, R., Bengtsson, J., Thörnblom, E., et al.[2021]
Repeated applications of Theta Burst stimulation (TBS) in rats showed complex effects on neuronal activity markers, with some markers increasing while others decreased, indicating that the response to TBS is not simply accumulative.
Specifically, while the expression of the vesicular glutamate transporter (VGLUT1) increased with stimulation, markers for inhibitory activity like GAD67 and calcium-binding proteins decreased, suggesting a nuanced interaction between excitatory and inhibitory neuronal responses to repeated TBS.
Dose-dependence of changes in cortical protein expression induced with repeated transcranial magnetic theta-burst stimulation in the rat.Volz, LJ., Benali, A., Mix, A., et al.[2016]

References

Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial. [2018]
Dorsomedial prefrontal theta burst stimulation to treat anhedonia, avolition, and blunted affect in schizophrenia or depression - a randomized controlled trial. [2021]
Dose-dependence of changes in cortical protein expression induced with repeated transcranial magnetic theta-burst stimulation in the rat. [2016]
Prolonged intermittent theta burst stimulation in the treatment of major depressive disorder: a case series. [2022]
Bilateral sequential theta burst stimulation for multiple-therapy-resistant depression: A naturalistic observation study. [2022]
Safety, tolerability and preliminary evidence for antidepressant efficacy of theta-burst transcranial magnetic stimulation in patients with major depression. [2019]
Accelerated theta-burst repetitive transcranial magnetic stimulation for depression in South Africa. [2020]
Accelerated theta burst stimulation for the treatment of depression: A randomised controlled trial. [2022]
Preliminary assessment of the therapeutic efficacy of continuous theta-burst magnetic stimulation (cTBS) in major depression: a double-blind sham-controlled study. [2018]